Scientific Online Resource System

Scripta Scientifica Medica

Oxydative status and atrial fibrillations

Zhaneta Georgieva


According to the recent epidemiological reports atrial fibrillation (AF) affects about 6 million people in Europe and the number is expected to double in the next 50 years (1). Because of the growing incidence, AF is considered as `the new epidemic` (2).
Despite being recognized as far back as ancient Greece and China, nowadays AF is a real challenge for cardiologists. The numerous antiarrhythmic drugs, namely blockers of !-adrenergic receptors and cardiac ion channels, as well as catheter ablation have inadequate efficacy on AF recurrences and progressive clinical course. Main limitation for these results is the poor understanding of arrhythmia pathogenesis (3). Thus, in the last years, the efforts of scientists are increasingly focused on the underlying mechanisms concerning AF initiation and recurrences.


editorial; Medical University of Varna

Full Text


Lip G, Caterina R, Savelieva I et al. ESC Committee for Practice Guidelines 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J., 2012;33:2719-2747.

Savelieva I, Camm J. Update on Atrial Fibrillation: Part I Clin. Cardiol., 2008;31:55-62.

Mayyas F, Alzoubi KH, Van Wagoner DR. Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling. Int J Cardiol., 2013;168(6):5135-5142.

Rasoli S, Kakouros N, Harling L et al. Antioxidant Vitamins in the Prevention of Atrial Fibrillation: What Is the Evidence? Cardiology Research and Practice, 2011, Article ID 164078, 8 pages.

Youn JY, Zhang J, Zhang Y et al. Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase. J Mol Cell Cardiol., 2013 Sep;62:72-9.

Gu WJ, Wu ZJ, Wang PF, Aung LH, Yin RX. N-Acetylcysteine supplementation for the prevention of atrial fibrillation after cardiac surgery: a meta-analysis of eight randomized controlled trials. BMC Cardiovasc Disord., 2012;12:10.

Article Tools
Email this article (Login required)
About The Author

Zhaneta Georgieva
Medical University of Varna

Head of Department of Propedeutics of Internal Diseases

Font Size